94 related articles for article (PubMed ID: 10211913)
1. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety.
Smith WT; Londborg PD; Blomgren SL; Tollefson GD; Sayler ME
J Clin Psychopharmacol; 1999 Apr; 19(2):125-31. PubMed ID: 10211913
[TBL] [Abstract][Full Text] [Related]
2. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
[TBL] [Abstract][Full Text] [Related]
4. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
Chappell AS; Bay JM; Botzum GD; Cohen ML
Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290
[TBL] [Abstract][Full Text] [Related]
5. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
6. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
Brawman-Mintzer O; Knapp RG; Nietert PJ
J Clin Psychiatry; 2005 Oct; 66(10):1321-5. PubMed ID: 16259547
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
9. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study.
Ivashchenko AA; Morozova MA; Vostokova NV; Beniashvily AG; Bukhanovskaya OA; Burminskiy DS; Egorova AN; Gluskina LY; Gorchakov DS; Karapetian RN; Kasimova LN; Kravchenko DV; Lepilkina TA; Merkulova EA; Mitkin OD; Penchul NA; Potanin SS; Rupchev GE; Ivachtchenko AV
J Psychiatr Res; 2021 Nov; 143():436-444. PubMed ID: 34656876
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR; DuPont RL; Hedges D; Haskins JT
J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
[TBL] [Abstract][Full Text] [Related]
13. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study.
Llorca PM; Spadone C; Sol O; Danniau A; Bougerol T; Corruble E; Faruch M; Macher JP; Sermet E; Servant D
J Clin Psychiatry; 2002 Nov; 63(11):1020-7. PubMed ID: 12444816
[TBL] [Abstract][Full Text] [Related]
15. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
17. Zatosetron. LY 191617, LY 277359.
Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
[No Abstract] [Full Text] [Related]
18. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
